Swiss rare disease biotech withdraws IPO to update its Nasdaq plans

Swiss rare disease biotech withdraws IPO to update its Nasdaq plans

Source: 
Endpoints
snippet: 

Months after it first went for a formal US listing, Relief Therapeutics is withdrawing its IPO application in what the rare disease player calls a change of plans.